

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/618,162	07/10/2003	Laszlo Vigh	CytRx/009 DIV2 4065	
1473 7	7590 08/22/2006		EXAMINER	
FISH & NEA ROPES & GR	VE IP GROUP	GEMBEH, SHIRLEY V		
	AY LLP E OF THE AMERICAS FL (ART UNIT	PAPER NUMBER	
NEW YORK,	NY 10020-1105		1614	
			DATE MAILED: 08/22/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

			Application No.	Applicant(s)				
Office Action Summary		10/618,162	VIGH ET AL.					
		Examiner	Art Unit					
			Shirley V. Gembeh	1614				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
WHIC - External after - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR CHEVER IS LONGER, FROM THE MINISTRICT IN THE MINISTRICT	AILING DA' of 37 CFR 1.136 nunication. atutory period will will, by statute, of	TE OF THIS COMMUNICATION 6(a). In no event, however, may a reply be tim Il apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONED	l. ely filed the mailing date of this communication. O (35 U.S.C. § 133).				
Status								
1)	Responsive to communication(s) file	d on						
	This action is FINAL . 2b) This action is non-final.							
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims							
4)⊠	4)⊠ Claim(s) <u>1-25</u> is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.							
5)	S) Claim(s) is/are allowed.							
6)□	Claim(s) is/are rejected.							
7)	Claim(s) is/are objected to.							
8)⊠	S)⊠ Claim(s) <u>1-25</u> are subject to restriction and/or election requirement.							
Applicati	on Papers							
9) The specification is objected to by the Examiner.								
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority u	nder 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:								
•	1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
	3. Copies of the certified copies of the priority documents have been received in this National Stage							
	application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.								
Attachment	` '		_					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date								
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) 5) Notice of Informal Patent Application (PTO-152)								
	Paper No(s)/Mail Date 6) Other:							

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-12, drawn to a method of increasing expression of a molecular chaperone by an eukaryotic cell comprising treating an eurakaryotic cell of a living mammalian organism that is exposed to a physiological stress with an effective amount of a chemical compound to increase the expression of a molecular chaperone by the cell with formula I.

Group II, claim(s) 13-19, drawn to a method of increasing activity of a molecular chaperone in an eurkaryotic cell of a living mammalian organism that is exposed comprising treating the cell that is exposed to a physiological stress with an effective amount of a chemical compound to increase the expression of a molecular chaperone by the cell with formula I.

Group III, claim(s) Claims 20-24, drawn to a method of treating disease connected with the function of the chaperon system or associated with the injury of the membrane by administering compound of formula I.

Group IV, claim(s) 25, drawn to a pharmaceutical composition for the treatment of cardiovascular, vascular, cerebral, allergic etc., with compound of formula 1.

The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the method of enhancing cellular chaperone can be used with another materially different compound (see enclosed article Sorensen et al-Microbial Cell Factories 47).

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

A is unsubstituted/substituted aryl or hetoaryl (Applicant needs to elect the specifically what the unsubstituted/substituted aryl or hetoaryl is).

R" is akyl or substituted alkyl (Applicant needs to elect the specifically what the akyl or substituted alkyl).

R¹ is H, unsubstituted/substituted straight or branch alkyl etc (Applicant needs to elect the specifically what the unsubstituted/substituted straight or branch alkyl is).

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims

are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 10/618,162

Art Unit: 1614

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shirley V. Gembeh whose telephone number is 571-272-8504. The examiner can normally be reached on 8:30 -5:00, Monday- Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

SVG 8/17/06 ARDIN H. MARSCHEL SUPERVISORY PATENT EXAMINER

Page 5